Other sepsis. Other specified sepsis
Conditions
Interventions
Intervention 1: Intervention group: 26 patients in the nanosilymarin supplement group will receive 70 mg nanosilymarin soft gelatin capsules, two together, twice a day for 5 days, along with an antibi
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age between 18 and 80 years Sepsis or septic shock in the intensive care unit (Sepsis is a life-threatening organ dysfunction caused by dysregulated host responses to infection. This organ dysfunction is defined by an acute change in the Sequential Organ Failure Assessment (SOFA) score of greater than or equal to 2 points from baseline following infection.) Signing the informed consent form
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C-reactive protein (CRP). Timepoint: It will be recorded for each patient once upon entering the study and again after receiving the last dose of nanosilymarin. Method of measurement: Blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum creatinine. Timepoint: It will be recorded for each patient once upon entering the study and again after receiving the last dose of nanosilymarin. Method of measurement: Blood sample.;White blood cell count. Timepoint: It will be recorded for each patient once upon entering the study and again after receiving the last dose of nanosilymarin. Method of measurement: Blood sample.;Platelet count. Timepoint: It will be recorded for each patient once upon entering the study and again after receiving the last dose of nanosilymarin. Method of measurement: Blood sample.;Neutrophils to lymphocytes ratio. Timepoint: It will be recorded for each patient once upon entering the study and again after receiving the last dose of nanosilymarin. Method of measurement: Blood sample.;Platelet to lymphocyte ratio. Timepoint: It will be recorded for each patient once upon entering the study and again after receiving the last dose of nanosilymarin. Method of measurement: Blood sample.;Total bilirubin and direct bilirubin. Timepoint: It will be recorded for each patient once upon entering the study and again after receiving the last dose of nanosilymarin. Method of measurement: Blood sample.;Serum lactate. Timepoint: It will be recorded for each patient once upon entering the study and again after receiving the last dose of nanosilymarin. Method of measurement: Blood sample.;SOFA score. Timepoint: It will be recorded for each patient once upon entering the study and again after receiving the last dose of nanosilymarin. Method of measurement: Blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHesamoddin Hosseinjani
Mashhad University of Medical Sciences
Outcome results
None listed